Privé de la loi sur la réforme du contentieux

This presentation contains forward-l ooking statements as defined in the Priv ate Securities Litigation Reform Act of 1995, as amended. Forward-looking st atements are statements that are no t historical facts. These statements include financial and product development projections and estimates and their underlying assumptions, statements regarding plans, objectives , intentions and expectations with re spect to future ev ents, operations, products and services, and statements regarding future performance. Forw ard-looking statements are generally identified by the words “expects,” “anticipates,” “ believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward- looking statements are reasonable, in vestors are cautioned that forward-lo oking information and statements are subject to various risks and uncertainties, many of which are difficu lt to predict and generally beyond the control of sanofi-aventis, that coul d cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking informati on and statements. These risks and uncertainties include among other thin gs, the uncertainties inherent in re search and development, future clinical data and analysis, in cluding post marketing, deci sions by regulatory authoriti es, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions re garding labeling and other matters that could affect the availability or commercial potential of such products candidates, th e absence of guarantee that the products candidates if approved will be commercially successf ul, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opport unities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statemen t Regarding Forward-Looking Statements” in sanofi- aventis’ annual report on Form 20-F fo r the year ended December 31, 2008.This presentation contains forward-l ooking statements as defined in the Priv ate Securities Litigation Reform Act of 1995, as amended. Forward-looking st atements are statements that are no t historical facts. These statements include financial and product development projections and estimates and their underlying assumptions, statements regarding plans, objectives , intentions and expectations with re spect to future ev ents, operations, products and services, and statements regarding future performance. Forw ard-looking statements are generally identified by the words “expects,” “anticipates,” “ believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward- looking statements are reasonable, in vestors are cautioned that forward-lo oking information and statements are subject to various risks and uncertainties, many of which are difficu lt to predict and generally beyond the control of sanofi-aventis, that coul d cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking informati on and statements. These risks and uncertainties include among other thin gs, the uncertainties inherent in re search and development, future clinical data and analysis, in cluding post marketing, deci sions by regulatory authoriti es, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions re garding labeling and other matters that could affect the availability or commercial potential of such products candidates, th e absence of guarantee that the products candidates if approved will be commercially successf ul, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opport unities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statemen t Regarding Forward-Looking Statements” in sanofi- aventis’ annual report on Form 20-F fo r the year ended December 31, 2008.This presentation contains forward-l ooking statements as defined in the Priv ate Securities Litigation Reform Act of 1995, as amended. Forward-looking st atements are statements that are no t historical facts. These statements include financial and product development projections and estimates and their underlying assumptions, statements regarding plans, objectives , intentions and expectations with re spect to future ev ents, operations, products and services, and statements regarding future performance. Forw ard-looking statements are generally identified by the words “expects,” “anticipates,” “ believes,” “intends,” “estimates,” “plans” and similar expressions. Although sanofi-aventis’ management believes that the expectations reflected in such forward- looking statements are reasonable, in vestors are cautioned that forward-lo oking information and statements are subject to various risks and uncertainties, many of which are difficu lt to predict and generally beyond the control of sanofi-aventis, that coul d cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking informati on and statements. These risks and uncertainties include among other thin gs, the uncertainties inherent in re search and development, future clinical data and analysis, in cluding post marketing, deci sions by regulatory authoriti es, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions re garding labeling and other matters that could affect the availability or commercial potential of such products candidates, th e absence of guarantee that the products candidates if approved will be commercially successf ul, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opport unities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under “Risk Factors” and “Cautionary Statemen t Regarding Forward-Looking Statements” in sanofi- aventis’ annual report on Form 20-F fo r the year ended December 31, 2008.This presentation contains forward-l ooking statements as defined in the Priv ate Securities

...